1. Home
  2. MEIP vs BZUN Comparison

MEIP vs BZUN Comparison

Compare MEIP & BZUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • BZUN
  • Stock Information
  • Founded
  • MEIP 2000
  • BZUN 2007
  • Country
  • MEIP United States
  • BZUN China
  • Employees
  • MEIP N/A
  • BZUN N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • BZUN Catalog/Specialty Distribution
  • Sector
  • MEIP Health Care
  • BZUN Consumer Discretionary
  • Exchange
  • MEIP Nasdaq
  • BZUN Nasdaq
  • Market Cap
  • MEIP 153.9M
  • BZUN 144.4M
  • IPO Year
  • MEIP 2003
  • BZUN N/A
  • Fundamental
  • Price
  • MEIP $4.91
  • BZUN $2.75
  • Analyst Decision
  • MEIP
  • BZUN Buy
  • Analyst Count
  • MEIP 0
  • BZUN 2
  • Target Price
  • MEIP N/A
  • BZUN $3.20
  • AVG Volume (30 Days)
  • MEIP 3.2M
  • BZUN 269.1K
  • Earning Date
  • MEIP 09-18-2025
  • BZUN 08-28-2025
  • Dividend Yield
  • MEIP N/A
  • BZUN N/A
  • EPS Growth
  • MEIP N/A
  • BZUN N/A
  • EPS
  • MEIP N/A
  • BZUN N/A
  • Revenue
  • MEIP N/A
  • BZUN $1,310,110,798.00
  • Revenue This Year
  • MEIP N/A
  • BZUN $5.27
  • Revenue Next Year
  • MEIP N/A
  • BZUN $3.46
  • P/E Ratio
  • MEIP N/A
  • BZUN N/A
  • Revenue Growth
  • MEIP 33.76
  • BZUN 6.77
  • 52 Week Low
  • MEIP $1.46
  • BZUN $2.12
  • 52 Week High
  • MEIP $9.00
  • BZUN $4.38
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 53.94
  • BZUN 53.52
  • Support Level
  • MEIP $4.62
  • BZUN $2.60
  • Resistance Level
  • MEIP $5.19
  • BZUN $2.82
  • Average True Range (ATR)
  • MEIP 0.46
  • BZUN 0.10
  • MACD
  • MEIP -0.16
  • BZUN 0.00
  • Stochastic Oscillator
  • MEIP 15.93
  • BZUN 47.37

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About BZUN Baozun Inc.

Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.

Share on Social Networks: